GleamWall
中文EN

SLS SELLAS Life Sciences Group, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1390478 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-37.8%
TTM EPS YoY28.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-40.3%
ROA-37.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6.6%
Debt / equity0.00x
Current ratio14.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
Cost of revenue$0$0
R&D expense$16.02M$19.10M
SG&A expense$12.25M$12.42M
Operating income-$28.27M-$31.51M
Pretax income-$26.86M-$30.88M
Income tax$0$0
Net income-$26.86M-$30.88M
EPS (basic)-0.25-0.50
EPS (diluted)-0.25-0.50
Weighted avg. shares (diluted)109.05M61.20M
Balance sheet
Cash & equivalents$71.79M$13.99M
Current assets$75.21M$16.33M
Goodwill$1.91M$1.91M
Total assets$78.34M$19.43M
Current liabilities$7.02M$9.51M
Total liabilities$7.47M$9.97M
Shareholders' equity$70.87M$9.46M
Shares outstanding153.10M73.98M
Cash flow statement
Operating cash flow-$28.39M-$35.40M
Investing cash flow—$0
Financing cash flow$86.30M$46.76M
Stock-based compensation$1.96M$1.56M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.